VERA
Vera Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$35.89
+2.57%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | (871.0K) | — | — | — | (846.0K) |
| Gross Profit | 871.0K | — | — | — | 846.0K |
| Operating Expenses | |||||
| R&D Expense | 262.1M | 215.3M | 126.2M | 78.2M | 69.8M |
| SG&A Expense | 153.9M | 100.2M | 41.0M | 23.8M | 21.9M |
| General & Admin Expense | 148.2M | 100.2M | 41.0M | 23.8M | — |
| Selling & Marketing Expense | 5.7M | — | — | — | — |
| Other Expenses | 879.0K | — | — | — | — |
| Total Operating Expenses | 416.9M | 315.5M | 167.2M | 102.0M | 91.7M |
| Cost and Expenses | 415.8M | 315.5M | 167.2M | 102.0M | 90.9M |
| Operating Income (EBIT) | (415.8M) | (315.5M) | (167.2M) | (102.0M) | (90.9M) |
| Non-Operating | |||||
| Interest Income | 36.4M | 24.5M | 20.7M | 8.0M | 1.8M |
| Interest Expense | 11.3M | 7.5M | 7.6M | 3.8M | 992.0K |
| Net Interest Income | 25.1M | 16.9M | 13.1M | 4.2M | 758.0K |
| Other Non-Op Income/Expense | 13.9M | 15.9M | 15.0M | 6.0M | 1.8M |
| Non-Operating Income (excl Interest) | (25.1M) | (23.4M) | (22.6M) | (9.8M) | (2.8M) |
| EBT (Pre-Tax Income) | (401.9M) | (299.6M) | (152.1M) | (96.0M) | (89.1M) |
| Income Tax Expense | (1.0K) | 1.0K | 1.0K | 1.0K | 1.0K |
| Bottom Line | |||||
| Net Income | (401.9M) | (299.6M) | (152.1M) | (96.0M) | (89.1M) |
| Earnings from Cont. Ops | (401.9M) | (299.6M) | (152.1M) | (96.0M) | (89.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (401.9M) | (299.6M) | (152.1M) | (96.0M) | (89.1M) |
| Per Share | |||||
| Basic EPS | ($5.86) | ($4.66) | ($2.75) | ($2.25) | ($3.35) |
| Diluted EPS | ($5.86) | ($4.66) | ($2.75) | ($2.25) | ($3.35) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 71.8M | 64.2M | 55.3M | 42.7M | 26.6M |
| Diluted Shares Outstanding | 71.8M | 64.2M | 55.3M | 42.7M | 26.6M |
| Profitability Metrics | |||||
| EBITDA | (390.0M) | (291.6M) | (144.4M) | (92.2M) | (88.9M) |
| D&A | 652.0K | 468.0K | 105.0K | 21.0K | (846.0K) |
| EBIT | (390.6M) | (292.1M) | (144.5M) | (92.2M) | (88.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026